Company Logo

• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications don't work for a majority of people who are depressed. A customized treatment could be the answer.

Cue is a digital intervention platform that converts passively collected smartphone sensor data into personalized micro-interventions designed to improve mental health. We examined the most effective-fitting personalized ML models to each subject, using Shapley values to discover their characteristic predictors. This revealed distinct features that changed mood in a predictable manner over time.

Predictors of Mood

Depression is one of the leading causes of mental illness.1 However, only about half of those who have the disorder receive treatment1. To improve the outcomes, doctors must be able identify and treat patients who are the most likely to benefit from certain treatments.

The treatment of depression can be personalized to help. Using sensors on mobile phones and an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from which treatments. Two grants were awarded that total more than $10 million, they will use these techniques to determine the biological and behavioral factors that determine responses to antidepressant medications as well as psychotherapy.

So far, the majority of research on predictors for postpartum depression treatment near me treatment effectiveness has centered on clinical and sociodemographic characteristics. These include demographics such as age, gender, and education, as well as clinical characteristics like symptom severity and comorbidities, as well as biological markers.

Very few studies have used longitudinal data to predict mood of individuals. Few studies also consider the fact that mood can differ significantly between individuals. Therefore, it is critical to develop methods that allow for the determination of different mood predictors for each person and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This allows the team to create algorithms that can detect different patterns of behavior and emotion that differ between individuals.

The team also devised a machine learning algorithm to identify dynamic predictors of the mood of each person's depression. The algorithm combines these personal characteristics into a distinctive "digital phenotype" for each participant.

This digital phenotype was found to be associated with CAT-DI scores, which is a psychometrically validated severity scale for symptom severity. However the correlation was tinny (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 1003) and varied widely among individuals.

Predictors of symptoms

Depression is the leading cause of disability in the world, but it is often untreated and misdiagnosed. In addition an absence of effective interventions and stigmatization associated with depressive disorders prevent many people from seeking help.

To aid in the development of a personalized treatment plan in order to provide a more personalized treatment, identifying patterns that can predict symptoms is essential. However, the current methods for predicting symptoms depend on the clinical interview which is unreliable and only detects a small number of features that are associated with depression.2

Machine learning can enhance the accuracy of the diagnosis and treatment of depression by combining continuous, digital behavioral phenotypes gathered from smartphones with a valid mental health tracker online (the Computerized Adaptive Testing depression treatment no medication Inventory CAT-DI). These digital phenotypes are able to capture a variety of distinct actions and behaviors that are difficult to document through interviews, and allow for continuous, high-resolution measurements.

The study comprised University of California Los Angeles students with mild to severe Postpartum Depression Treatment symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were routed to online support or in-person clinical treatment depending on their depression severity. Participants with a CAT-DI score of 35 or 65 were given online support by a coach and those with a score 75 were sent to in-person clinics for psychotherapy.

Participants were asked a set of questions at the beginning of the study about their psychosocial and demographic characteristics as well as their socioeconomic status. The questions included age, sex, and education, marital status, financial status, whether they were divorced or not, their current suicidal thoughts, intent or attempts, as well as how often they drank. Participants also rated their level of depression severity on a scale of 0-100 using the CAT-DI. The CAT-DI tests were conducted every other week for the participants that received online support, and weekly for those receiving in-person support.

Predictors of the Reaction to Treatment

Research is focused on individualized depression treatment resistant depression treatment. Many studies are focused on identifying predictors, which will aid clinicians in identifying the most effective drugs for each person. In particular, pharmacogenetics identifies genetic variants that influence how the body's metabolism reacts to antidepressants. This allows doctors to select the medications that are most likely to be most effective for each patient, minimizing the time and effort involved in trial-and-error procedures and avoid any adverse effects that could otherwise slow the progress of the patient.

Another promising approach is building models of prediction using a variety of data sources, combining the clinical information with neural imaging data. These models can be used to determine which variables are the most likely to predict a specific outcome, such as whether a drug will help with symptoms or mood. These models can also be used to predict a patient's response to an existing treatment, allowing doctors to maximize the effectiveness of their treatment currently being administered.

A new generation employs machine learning techniques like the supervised and classification algorithms, regularized logistic regression and tree-based techniques to combine the effects from multiple variables and increase the accuracy of predictions. These models have been demonstrated to be effective in predicting treatment outcomes, such as response to antidepressants. These approaches are gaining popularity in psychiatry and it is likely that they will become the norm for future clinical practice.

Research into depression's underlying mechanisms continues, as well as ML-based predictive models. Recent research suggests that the disorder is linked with neurodegeneration in particular circuits. This theory suggests that a individualized treatment for depression will be based upon targeted treatments that restore normal function to these circuits.

One way to do this is through internet-delivered interventions that offer a more individualized and personalized experience for patients. For example, one study discovered that a web-based treatment was more effective than standard care in reducing symptoms and ensuring an improved quality of life for people with MDD. Furthermore, a randomized controlled trial of a personalized approach to treating depression showed steady improvement and decreased side effects in a significant proportion of participants.

Predictors of adverse effects

In the treatment of depression one of the most difficult aspects is predicting and identifying the antidepressant that will cause no or minimal side effects. Many patients experience a trial-and-error approach, using several medications prescribed until they find one that is safe and effective. Pharmacogenetics is an exciting new avenue for a more efficient and targeted approach to selecting antidepressant treatments.

There are a variety of predictors that can be used to determine the antidepressant that should be prescribed, such as gene variations, phenotypes of the patient such as ethnicity or gender and co-morbidities. To determine the most reliable and reliable predictors of a specific treatment, controlled trials that are randomized with larger samples will be required. This is because the identifying of interaction effects or moderators may be much more difficult in trials that only focus on a single instance of treatment per participant, rather than multiple episodes of treatment over time.

Additionally, the prediction of a patient's response to a particular medication will likely also require information about symptoms and comorbidities in addition to the patient's prior subjective experience of its tolerability and effectiveness. Presently, only a handful of easily assessable sociodemographic and clinical variables appear to be reliable in predicting the response to MDD like age, gender race/ethnicity BMI and the presence of alexithymia and the severity of depression symptoms.

Many issues remain to be resolved in the use of pharmacogenetics to treat depression. first line treatment for depression, a clear understanding of the genetic mechanisms is needed and an understanding of what is a reliable indicator of treatment response. In addition, ethical issues, such as privacy and the responsible use of personal genetic information, should be considered with care. The use of pharmacogenetics may, in the long run reduce stigma associated with mental health treatments and improve treatment outcomes. As with any psychiatric approach, it is important to take your time and carefully implement the plan. For now, it is ideal to offer patients various depression medications that work and encourage them to talk openly with their doctor.